The FDA premarket approval database lists Irvine Biomedical, Inc. (IBI) at 2375 Morse Ave., Irvine, CA 92614, as the applicant on P040042, a Class 3 percutaneous cardiac ablation catheter for treatment of atrial flutter under product code OAD and the Cardiovascular advisory committee. The original approval, dated November 18, 2005, covers the Therapy Dual 8 Cardiac Ablation System together with the Theram 8mm Thermister Ablation Catheter and Safire TX Ablation Catheter. A later 30-day notice supplement, P040042/S060, was decided September 3, 2026. [2][5][1]
Documented product and system components
The approval order describes the device generic name as electrophysiology ablation catheter and cardiac ablation generator (RF), with trade names IBI Therapy Dual 8 Ablation Catheter and IBI-1500T6 (USA) Cardiac Ablation Generator. The indication statement in the approval record limits use to treatment of typical atrial flutter, and the summary states the catheter is intended for use with the IBI-1500T6 (USA) 100 watt generator at a maximum of 100 watts. [5][2]
The FDA record classifies the generic device as a catheter, percutaneous, cardiac ablation, for treatment of atrial flutter, device class 3, product code OAD, reviewed by the Cardiovascular advisory committee. The same record lists the applicant address as 2375 Morse Ave., Irvine, CA 92614, which is a filing address rather than a verified corporate headquarters. [2][1]
Original approval and supplement activity
P040042 received approval on November 18, 2005, with a date received of October 4, 2004, docket number 05M-0476 and a Federal Register notice date of November 28, 2005. The expedited review flag is recorded as N. [2]
Supplement P040042/S060 is a 30-Day Notice under supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, received August 7, 2026 and decided September 3, 2026 with decision code OK30. Its approval order statement describes adding an alternate epoxy in the manufacture of the temperature sensor. [1]
FDA pages for P040042 and its supplements note that a device with supplements may have a changed description, function or indication, and direct readers to the supplements for an up-to-date view. [4][8][9]
What the supplied collection shows
The MedtechLedger snapshot links two PMA records to this applicant, both under P040042. Decision counts across that collection are one OK30 and one APPR; the smaller record sample of two entries shows the same one-and-one split. These are counts of supplied filings as of the snapshot date, not measures of total portfolio, sales or safety performance. [1][2]
No recall records appear in the supplied sample, and the sources do not establish ownership, parent companies, brand relationships, customers, commercial availability or post-approval clinical results. Those points remain unknown from the public information. [2][5]


